Report cover image

Neuropathic Pain - Pipeline Insight, 2025

Publisher DelveInsight
Published Apr 01, 2025
Length 60 Pages
SKU # DEL19995619

Description

Neuropathic Pain Overview

""Neuropathic Pain Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Neuropathic Pain market. A detailed picture of the Neuropathic Pain pipeline landscape is provided, which includes the disease overview and Neuropathic Pain treatment guidelines. The assessment part of the report embraces in-depth Neuropathic Pain commercial assessment and clinical assessment of the Neuropathic Pain pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Neuropathic Pain collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

Neuropathic Pain of Pipeline Development Activities

The report provides insights into:
  • All of the companies that are developing therapies for the treatment of Neuropathic Pain with aggregate therapies developed by each company for the same.
  • Different therapeutic candidates segmented into early-stage, mid-stage and late stage of development for the Neuropathic Pain treatment.
  • Neuropathic Pain key players involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of Neuropathic Pain market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university web sites and industry-specific third-party sources, etc.

Neuropathic Pain Analytical Perspective by DelveInsight

In-depth Neuropathic Pain Commercial Assessment of products

This report provides a comprehensive commercial assessment of therapeutic drugs that have been included, which comprises of collaborations, licensing, and acquisition deal value trends. The report also covers company-company collaborations (licensing/partnering), company-academia collaborations, and acquisition analysis in both graphical and tabulated form in a detailed manner.

Neuropathic Pain Clinical Assessment of products

The report comprises of comparative clinical assessment of products by development stage, product type, and route of administration, molecule type, and MOA type across this indication.

Scope of the Report
  • The Neuropathic Pain report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Neuropathic Pain across the complete product development cycle, including all clinical and nonclinical stages.
  • It comprises of detailed profiles of Neuropathic Pain therapeutic products with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details
  • Detailed Neuropathic Pain research and development progress and trial details, results wherever available, are also included in the pipeline study.
  • Coverage of dormant and discontinued pipeline projects along with the reasons if available across Neuropathic Pain.
Report Highlights
  • A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Neuropathic Pain.
  • In the coming years, the Neuropathic Pain market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics that are working to assess challenges and seek opportunities that could influence Neuropathic Pain R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • A detailed portfolio of major pharma players who are involved in fueling the Neuropathic Pain treatment market. Several potential therapies for Neuropathic Pain are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Neuropathic Pain market size in the coming years.
  • Our in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of Neuropathic Pain) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.
Key Questions
  • What are the current options for Neuropathic Pain treatment?
  • How many companies are developing therapies for the treatment of Neuropathic Pain?
  • What are the principal therapies developed by these companies in the industry?
  • How many therapies are developed by each company for the treatment of Neuropathic Pain?
  • How many Neuropathic Pain emerging therapies are in early-stage, mid-stage, and late stage of development for the treatment of Neuropathic Pain?
  • Out of total pipeline products, how many therapies are given as a monotherapy and in combination with other therapies?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, and major licensing activities that will impact Neuropathic Pain market?
  • Which are the dormant and discontinued products and the reasons for the same?
  • What is the unmet need for current therapies for the treatment of Neuropathic Pain?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing Neuropathic Pain therapies?
  • What are the clinical studies going on for Neuropathic Pain and their status?
  • What are the results of the clinical studies and their safety and efficacy?
  • What are the key designations that have been granted for the emerging therapies for Neuropathic Pain?
  • How many patents are granted and pending for the emerging therapies for the treatment of Neuropathic Pain?

Table of Contents

60 Pages
1. Report Introduction
2. Neuropathic Pain
2.1. Overview
2.2. History
2.3. Neuropathic Pain Symptoms
2.4. Causes
2.5. Pathophysiology
2.6. Neuropathic Pain Diagnosis
2.6.1. Diagnostic Guidelines
3. Neuropathic Pain Current Treatment Patterns
3.1. Neuropathic Pain Treatment Guidelines
4. Neuropathic Pain - DelveInsight's Analytical Perspective
4.1. In-depth Commercial Assessment
4.1.1. Neuropathic Pain companies collaborations, Licensing, Acquisition -Deal Value Trends
4.1.1.1. Assessment Summary
4.1.2. Neuropathic Pain Collaboration Deals
4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis
4.1.2.2. Company-University Collaborations (Licensing / Partnering) Analysis
4.1.2.3. Neuropathic Pain Acquisition Analysis
5. Therapeutic Assessment
5.1. Clinical Assessment of Pipeline Drugs
5.1.1. Assessment by Phase of Development
5.1.2. Assessment by Product Type (Mono / Combination)
5.1.2.1. Assessment by Stage and Product Type
5.1.3. Assessment by Route of Administration
5.1.3.1. Assessment by Stage and Route of Administration
5.1.4. Assessment by Molecule Type
5.1.4.1. Assessment by Stage and Molecule Type
5.1.5. Assessment by MOA
5.1.5.1. Assessment by Stage and MOA
5.1.6. Assessment by Target
5.1.6.1. Assessment by Stage and Target
6. Neuropathic Pain Late Stage Products (Phase-III)
7. Neuropathic Pain Mid Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Neuropathic Pain Discontinued Products
13. Neuropathic Pain Product Profiles
13.1. Drug Name: Company
13.1.1. Product Description
13.1.1.1. Product Overview
13.1.1.2. Mechanism of action
13.1.2. Research and Development
13.1.2.1. Clinical Studies
13.1.3. Product Development Activities
13.1.3.1. Collaboration
13.1.3.2. Agreements
13.1.3.3. Acquisition
13.1.3.4. Patent Detail
13.1.4. Tabulated Product Summary
13.1.4.1. General Description Table
Detailed information in the report
14. Neuropathic Pain Key Companies
15. Neuropathic Pain Key Products
16. Dormant and Discontinued Products
16.1. Dormant Products
16.1.1. Reasons for being dormant
16.2. Discontinued Products
16.2.1. Reasons for the discontinuation
17. Neuropathic Pain Unmet Needs
18. Neuropathic Pain Future Perspectives
19. Neuropathic Pain Analyst Review
20. Appendix
21. Report Methodology
21.1. Secondary Research
21.2. Expert Panel Validation

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us